Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans
South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The company has moved ahead of a small pack of competitors and gained regulatory approval and market access in eight territories through a focus on gathering strong evidence to support algorithms.
You may also be interested in...
FDA’s SaMD/SiMD Guidance Could Mean Documentation Headaches For Some Software Makers, Attorney Says
A long-awaited draft guidance from the US agency delineates which medical software devices will need additional documentation based on risk – but it could also mean more work for some manufacturers.
FDA Issues 5-Point Action Plan For Artificial Intelligence/Machine Learning-Based SaMD
A new guidance document and a promise to hold a public workshop are just two commitments made by the US agency in a 12 January action plan aimed at AI/ML-based software as a medical device.
GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.